Review article · 2025

Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape

Preetika Govil, Joshua T. Kantrowitz

CNS Drugs, 39(3), 243–262 · Published 12 January 2025 · DOI 10.1007/s40263-024-01151-7

View at the publisherCite this paper

In brief

“Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape” is a 2025 review article by Preetika Govil and Joshua T. Kantrowitz, published in CNS Drugs. OpenAlex counts 32 citations as of 20 November 2026, which puts it in the top 1% of works published in 2025 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
32
Most cited in
2026 (20)
Field-weighted impact
3.45
References
197
Authors
2

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Govil, P., & Kantrowitz, J. T. (2025). Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape. CNS Drugs, 39(3), 243–262. https://doi.org/10.1007/s40263-024-01151-7

MLA 9

Govil, Preetika, and Joshua T. Kantrowitz. “Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.” CNS Drugs, vol. 39, no. 3, 2025, pp. 243–262. https://doi.org/10.1007/s40263-024-01151-7.

Chicago

Govil, Preetika and Joshua T. Kantrowitz. 2025. “Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.” CNS Drugs 39 (3): 243–262. https://doi.org/10.1007/s40263-024-01151-7.

Harvard

Govil, P. and Kantrowitz, J. T. (2025) ‘Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape’, CNS Drugs, 39(3), pp. 243–262. doi:10.1007/s40263-024-01151-7.

IEEE

P. Govil and J. T. Kantrowitz, “Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape,” CNS Drugs, vol. 39, no. 3, pp. 243–262, 2025, doi: 10.1007/s40263-024-01151-7.

BibTeX

@article{govil2025negative,
  title     = {{Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape}},
  author    = {Govil, Preetika and Kantrowitz, Joshua T.},
  journal   = {CNS Drugs},
  year      = {2025},
  volume    = {39},
  number    = {3},
  pages     = {243--262},
  doi       = {10.1007/s40263-024-01151-7},
  url       = {https://doi.org/10.1007/s40263-024-01151-7}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • schizophrenia
  • negative symptoms
  • avolition
  • alogia
  • anhedonia
  • asociality
  • off-label drug use
  • investigational drugs

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Govil, P., & Kantrowitz, J. T. (2025). Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape. CNS Drugs, 39(3), 243–262. https://doi.org/10.1007/s40263-024-01151-7

How many times has this paper been cited?

32 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Preetika Govil, Joshua T. Kantrowitz.

What is the DOI of this paper?

10.1007/s40263-024-01151-7, permanently at https://doi.org/10.1007/s40263-024-01151-7. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.